Abstract YO25
Case summary
Background
Pembrolizumab is an immune checkpoint inhibitor, approved in recurrent head and neck cancer. Its use has been associated with hyperprogression, a phenomenon of extraordinarily rapid tumor progression in patients undergoing immunotherapy. Here, we report a case that showed hyperprogression after pembrolizumab in recurrent oropharyngeal cancer and the use of nab-paclitaxel as salvage treatment.
Methods
The patient was a 70 years old man with recurrent base of tongue cancer, who had progressed 2 months after receiving 2 cycles of cisplatin and 5-fluorouracil, followed by concurrent chemoradiotherapy (70Gy in 35 fractions over 7 weeks).
PD-L1 testing was done, which expressed 1-50% membrane positivity. He received second line treatment of intravenous Pembrolizumab 100mg, administered 3 weekly.
Clinical and radiological assessments were done, comparing the baseline CT scan and the CT scan after immunotherapy. Hyperprogression was confirmed by measuring the tumor growth kinetics (TGK). Hyperprogression is defined as a TGK ratio >2 with rapid progression.
The patient was started on intravenous nab-paclitaxel(125mg/m2), carboplatin (AUC 2.5), and bevacizumab (100mg) weekly for 2 weeks, administered 3 weekly after confirmation of hyperprogression with pembrolizumab treatment.
Results
14 days after the administration of the first cycle of Pembrolizumab, patient developed bigger tongue swelling, occupying the whole oral cavity protruding beyond the lips. Hyperprogression was confirmed with a CT scan, where a larger tongue mass was observed (67% enlargement) with new lung lesions and a TGK of 3.
Patient review 3 weeks after cycle 1 of nab-paclitaxel, carboplatin and bevacizumab showed smaller tongue swelling. He was given a total of 3 cycles of chemotherapy but acquired neutropenia and pneumonia after cycle 2 and tumor bleed after cycle 3. He died of the disease 110 days after receiving his chemotherapy.
Conclusion
It is important to be aware that hyperprogression can occur early in the treatment using pembrolizumab. If used judiciously, nab-paclitaxel can be effective as salvage treatment in hyperprogression of oropharyngeal cancer.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
284P - Differences in disease characteristics and survival outcomes of follicular lymphoma in young adults and older population: An institutional analysis
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract
285TiP - Phase II, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667
Presenter: Christine Mauz-koerholz
Session: Poster display session
Resources:
Abstract
294P - Validation of the 8th edition of AJCC/UICC staging system for nasopharyngeal carcinoma: Results from a non-endemic cohort with long-term follow-up
Presenter: Li-rong Wu
Session: Poster display session
Resources:
Abstract
295P - Development and validation of M1 substages for previously untreated metastatic nasopharyngeal carcinoma
Presenter: Sik Kwan Chan
Session: Poster display session
Resources:
Abstract
296P - Nasopharyngeal carcinoma: A retrospective review of outcome in a single institution
Presenter: Wan Ping Ch' ng
Session: Poster display session
Resources:
Abstract
297P - Global longitudinal assessment of treatment outcomes in nasopharyngeal carcinoma (GLANCE-NPC) study
Presenter: Myung-Ju Ahn
Session: Poster display session
Resources:
Abstract
298P - Long-term complication and outcomes after induction chemotherapy with TPF followed by chemoradiotherapy for nasopharyngeal cancer
Presenter: Sang-Hee Cho
Session: Poster display session
Resources:
Abstract
299P - Weekly versus triweekly concurrent chemoradiation for nasopharyngeal cancer
Presenter: Sudibio Sudibio
Session: Poster display session
Resources:
Abstract
300P - Endoscopic nasopharyngectomy for localized stage I nasopharyngeal carcinoma
Presenter: Ming-Yuan Chen
Session: Poster display session
Resources:
Abstract
301P - Oncological outcome following 3 Drug NACT for Bucco-Alveolar carcinoma with Supra-notch ITF extension
Presenter: Karan Gupta
Session: Poster display session
Resources:
Abstract